Compare Grab Holdings Ltd. (GRAB) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Grab Holdings Ltd. vs Novo Nordisk A/S — how do they compare? Grab Holdings Ltd. trades at $3.7 (market cap $15.26B), while Novo Nordisk A/S trades at $46.03 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 13.6× Grab Holdings Ltd.'s market cap, and Novo Nordisk A/S pays a 3.81% dividend while Grab Holdings Ltd. pays none. Which is the better fit depends on your goals.
| GRAB | NVO | |
|---|---|---|
Market Cap | $15.26B | $207.85B |
Sector | Technology | Health |
52-Week High | $6.45 | $63.98 |
52-Week Low | $3.27 | $35.29 |
Enterprise Value | $10.99B | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GRAB trades at $3.67, up 0.27% today, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. Revenue grew to $3.37B in 2025, with net income turning positive at $268M, reflecting improved profitability. The company raised its 2026 guidance after Q2 results, driven by on-demand and financial services growth. Analyst consensus is strongly bullish with an average price target of $5.86, implying 58% upside.
The outlook is positive given consistent earnings outperformance and raised guidance, but risks include high valuation (P/E 34), insider selling, and projected negative cash flow in 2026. Investors should weigh growth momentum against execution challenges in competitive Southeast Asian markets.
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Grab Holdings Ltd.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
